Abstract:Background: The use of single-chain variable fragments (scFvs) for treating human diseases, such as cancer and immune system disorders, has attracted significant attention. However, a critical drawback of scFv is its extremely short serum half-life, which limits its therapeutic potential. Thus, there is a critical need to prolong the serum half-life of the scFv for clinical applications. One promising serum half-life extender for therapeutic proteins is human serum albumin (HSA), which is the most abundant protein in human serum, known to have an exceptionally long serum half-life. However, conjugating a macromolecular half-life extender to a small protein, such as scFv, often results in a significant loss of its critical properties. Results: In this study, we conjugated the HSA to a permissive site of scFv to improve pharmacokinetic profiles. To ensure minimal damage to the antigen-binding capacity of scFv upon HSA conjugation, we employed a site-specific conjugation approach using a heterobifunctional crosslinker that facilitates thiol-maleimide reaction and inverse electron-demand Diels-Alder reaction (IEDDA). As a model protein, we selected 4D5scFv, derived from trastuzumab, a therapeutic antibody used in human epithermal growth factor 2 (HER2)-positive breast cancer treatment. We introduced a phenylalanine analog containing a very reactive tetrazine group (frTet) at conjugation site candidates predicted by computational methods. Using the linker TCO-PEG4-MAL, a single HSA molecule was site-specifically conjugated to the 4D5scFv (4D5scFv-HSA). The 4D5scFv-HSA conjugate exhibited HER2 binding affinity comparable to that of unmodified 4D5scFv. Furthermore, in pharmacokinetic profile in mice, the serum half-life of 4D5scFv-HSA was approximately 12 h, which is 85 times longer than that of 4D5scFv. Conclusions: The antigen binding results and pharmacokinetic profile of 4D5scFv-HSA demonstrate that the site-specifically albumin-conjugated scFv retained its binding affinity with a prolonged serum half-life. In conclusion, we developed an effective strategy to prepare site-specifically albumin-conjugated 4D5scFv, which can have versatile clinical applications with improved efficacy.

Albumin Fusion at the N-Terminus or C-Terminus of HM-3 Leads to Improved Pharmacokinetics and Bioactivities

HM-3-HSA exhibits potent anti-angiogenesis and antitumor activity in hepatocellular carcinoma

Effectiveness of HM-3-HSA on Inhibiting Cancer Cell Migration and Metastasis.

Development and Characterization of a Novel Fusion Protein of a Mutated Granulocyte Colony-Stimulating Factor and Human Serum Albumin in Pichia Pastoris.

In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by Different Polyethylene Glycols (PEG)

The Protective Effect Of A Long-Acting And Multi-Target Hm-3-Fc Fusion Protein In Rheumatoid Arthritis

In Vivo Pharmacokinetics, Immunogenicity and Mechanism of PEGylated Antitumor Polypeptide

Development of a novel albumin-based and maleimidopropionic acid-conjugated peptide with prolonged half-life and increased in vivo anti-tumor efficacy

[Corrigendum] in Vitro and in Vivo Activities of an Antitumor Peptide HM-3: A Special Dose-Efficacy Relationship on an HCT‑116 Xenograft Model in Nude Mice.

Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris.

Bioactivity and pharmacokinetics of two human serum albumin–thymosin α1-fusion proteins, rHSA-Tα1 and rHSA-L-Tα1, expressed in recombinant Pichia pastoris

Half‐life extension of single‐domain antibody–drug conjugates by albumin binding moiety enhances antitumor efficacy

Abstract B36: Human Serum Albumin and Affibody Fusion Proteins for Targeted Drug Delivery to HER2 Positive Cells

Studies of poly(ethylene glycol) modification of HM-3 polypeptides.

Fusion of an Albumin-Binding Domain Extends the Half-Life of Immunotoxins.

Human Serum Albumin And P53-Activating Peptide Fusion Protein Is Able To Promote Apoptosis And Deliver Fatty Acid-Modified Molecules

The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy

An Integrin Αvβ3 Antagonistic Modified Peptide Inhibits Tumor Growth Through Inhibition of the ERK and AKT Signaling Pathways.

Human Serum Albumin and HER2-Binding Affibody Fusion Proteins for Targeted Delivery of Fatty Acid-Modified Molecules and Therapy.

Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation

A comparative study on the effects of human serum albumin and α-melanocyte-stimulating hormone fusion proteins on the anti-neuroinflammatory in the central nervous system of adult mice